Recent Updates
Recently added Catalysts

VK3019

Phase 1

Obese Adults | Small Molecules | Metabolic |Viking Therapeutics, Inc.|Trials Updated: Sep 29, 2026

VK3019 target and mechanism

Molecular targetAmylin Receptor
Target classReceptor
ModalitySmall Molecules

Also known as SC VK3019

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindCONTROLLED
Total Trials1
Total Enrollment56

FDA Designations

No designations recorded

VK3019 clinical trials

VK3019 · 1 trial · 1 indication

Phase 1 1
NCT07846033A Phase 1 Study of VK3019 in Overweight and Obese Adults Without ComorbiditiesObese Adults
RECRUITING56 Analytics
PHASE1RECRUITING
A Phase 1 Study of VK3019 in Overweight and Obese Adults Without Comorbidities
Obese AdultsUnlock trial analytics

Study Endpoints

Primary Endpoints

Evaluate the safety of single doses of subcutaneous administration of VK3019
36 days

-Incidence of treatment emergent adverse events (TEAEs) and treatment emergent serious adverse events (TESAEs)

Secondary Endpoints

Evaluate the Pharmacokinetic profile of single doses of subcutaneous administration of VK3019
36 days
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelSEQUENTIAL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
VK3019 Dose Level 1EXPERIMENTALSingle-dose VK3019 or placebo administered subcutaneously
VK3019 Dose Level 2EXPERIMENTALSingle-dose VK3019 or placebo administered subcutaneously
VK3019 Dose Level 3EXPERIMENTALSingle-dose VK3019 or placebo administered subcutaneously
VK3019 Dose Level 4EXPERIMENTALSingle-dose VK3019 or placebo administered subcutaneously
VK3019 Dose Level 5EXPERIMENTALSingle-dose VK3019 or placebo administered subcutaneously
VK 3019 Dose Level 6EXPERIMENTALSingle-dose VK3019 or placebo administered subcutaneously
VK3019 Dose Level 7EXPERIMENTALSingle-dose VK3019 or placebo administered subcutaneously

Interventions

NameTypeDescription
SC VK3019DRUGSingle dose VK3019
Matching placeboDRUGSingle dose matching placebo
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 60 Years
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * Must be capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF). * Participants must be medically healthy, with no significant medical history, have no clinically significant abnormali...

Countries:United States
Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

LOWSep 29, 2026NCT07846033NEW_TRIAL: changed
LOWSep 29, 2026NCT07846033NEW_TRIAL: changed

Frequently asked questions about VK3019

What is VK3019?

VK3019 is an investigational small molecule drug being developed by Viking Therapeutics, Inc. for the treatment of obesity in adults. It is in Phase 1 clinical development and is designed to act on the amylin receptor. VK3019 has not been approved by the FDA and remains under clinical study.

What is VK3019 used for in obese adults?

VK3019 is being studied for use in overweight and obese adults without comorbidities. The ongoing Phase 1 trial is evaluating the drug in this population. It is an investigational therapy and has not been approved for any indication.

What does VK3019 target?

VK3019 targets the amylin receptor, a receptor involved in metabolic regulation. By acting on this receptor, the drug is being developed as a potential treatment for obesity. The amylin receptor is the primary molecular target of VK3019.

Who is developing VK3019?

VK3019 is being developed by Viking Therapeutics, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker VKTX. Viking Therapeutics is responsible for the clinical development of VK3019.

What phase is VK3019 in?

VK3019 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The Phase 1 program is currently ongoing.

What clinical trials is VK3019 in?

VK3019 is being evaluated in a Phase 1 trial, NCT07846033, titled A Phase 1 Study of VK3019 in Overweight and Obese Adults Without Comorbidities. The trial is recruiting and plans to enroll 56 participants in the United States. It is randomized, double-blind, and controlled.

Is VK3019 the same as SC VK3019?

Yes, VK3019 is also known as SC VK3019. Both names refer to the same investigational drug candidate being developed by Viking Therapeutics for obesity. The alternative name SC VK3019 may appear in some references.